BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/27/2019 4:11:15 AM | Browse: 1135 | Download: 1570
 |
Received |
|
2018-12-07 06:09 |
|
Peer-Review Started |
|
2018-12-09 13:11 |
|
To Make the First Decision |
|
2019-01-11 06:13 |
|
Return for Revision |
|
2019-01-14 02:49 |
|
Revised |
|
2019-01-17 10:01 |
|
Second Decision |
|
2019-01-25 10:04 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-01-26 05:34 |
|
Articles in Press |
|
2019-01-26 05:34 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-02-26 07:41 |
|
Publish the Manuscript Online |
|
2019-02-27 04:11 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house
editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Current and future pharmacological therapies for managing cirrhosis and its complications
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
David Kockerling, Rooshi Nathwani, Roberta Forlano, Pinelopi Manousou, Benjamin H Mullish and Ameet Dhar |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| NIHR |
|
| MRC |
MR/R00875/1 |
| EASL |
|
|
| Corresponding Author |
Ameet Dhar, BSc, MBBS, MRCP, PhD, Attending Doctor, Liver Unit/Division of Integrative Systems Medicine and Digestive Disease, Imperial College London, 10th Floor, QEQM Wing, St Mary’s Hospital Campus, South Wharf Road, Paddington, London W2 1NY, United Kingdom. a.dhar@imperial.ac.uk |
| Key Words |
Cirrhosis; Beta-blockers; Rifaximin; Diuretics; Statins; Proton pump inhibitors; Pharmacology |
| Core Tip |
Pharmacological therapy is central to the management of cirrhosis and its complications. Whilst there has been recent debate about the safety of beta-blockade in patients with ascites, conversely there is growing interest in potential benefits relating to a reduction in gut bacterial translocation and hepatocellular carcinoma risk. In addition to its well-established role in treating hepatic encephalopathy, rifaximin may also have a key role in preventing secondary infections. In this review, we summarise these and other uncertainties, controversies and novel developments related to pharmacotherapy in the clinical management of chronic liver disease. |
| Publish Date |
2019-02-27 04:11 |
| Citation |
Kockerling D, Nathwani R, Forlano R, Manousou P, Mullish BH, Dhar A. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019; 25(8): 888-908 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i8/888.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i8.888 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
